240 related articles for article (PubMed ID: 33900042)
1. Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline-based chemotherapy.
Loucks CM; Yan K; Tanoshima R; Ross CJD; Rassekh SR; Carleton BC
Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():95-99. PubMed ID: 33900042
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients.
Vargas-Neri JL; Carleton B; Ross CJ; Medeiros M; Castañeda-Hernández G; Clark P
Pharmacogenomics; 2022 Apr; 23(5):291-301. PubMed ID: 35147047
[No Abstract] [Full Text] [Related]
3. Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity.
Siemens A; Rassekh SR; Ross CJD; Carleton BC
Ther Drug Monit; 2023 Jun; 45(3):337-344. PubMed ID: 36728273
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.
Chang VY; Wang JJ
Curr Oncol Rep; 2018 Apr; 20(7):52. PubMed ID: 29713898
[TBL] [Abstract][Full Text] [Related]
5. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
Visscher H; Ross CJ; Rassekh SR; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Rogers PC; Rieder MJ; Carleton BC; Hayden MR;
Pediatr Blood Cancer; 2013 Aug; 60(8):1375-81. PubMed ID: 23441093
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
Visscher H; Ross CJ; Rassekh SR; Barhdadi A; Dubé MP; Al-Saloos H; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Brown AM; Rogers PC; Phillips MS; Rieder MJ; Carleton BC; Hayden MR;
J Clin Oncol; 2012 May; 30(13):1422-8. PubMed ID: 21900104
[TBL] [Abstract][Full Text] [Related]
7. Association between genetic variants of transmembrane transporters and susceptibility to anthracycline-induced cardiotoxicity: Current understanding and existing evidence.
Ni MM; Yang JF; Miao J; Xu J
Clin Genet; 2024 Feb; 105(2):115-129. PubMed ID: 37961936
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.
Aminkeng F; Ross CJ; Rassekh SR; Hwang S; Rieder MJ; Bhavsar AP; Smith A; Sanatani S; Gelmon KA; Bernstein D; Hayden MR; Amstutz U; Carleton BC;
Br J Clin Pharmacol; 2016 Sep; 82(3):683-95. PubMed ID: 27197003
[TBL] [Abstract][Full Text] [Related]
9. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Cheuk DK; Sieswerda E; van Dalen EC; Postma A; Kremer LC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008011. PubMed ID: 27552363
[TBL] [Abstract][Full Text] [Related]
10. Is there scope for better individualisation of anthracycline cancer chemotherapy?
Sallustio BC; Boddy AV
Br J Clin Pharmacol; 2021 Feb; 87(2):295-305. PubMed ID: 33118175
[TBL] [Abstract][Full Text] [Related]
11. Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer.
Petrykey K; Andelfinger GU; Laverdière C; Sinnett D; Krajinovic M
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):865-883. PubMed ID: 32772754
[TBL] [Abstract][Full Text] [Related]
12. The Role of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 Single-nucleotide Polymorphisms in the Doxorubicin-induced Cardiotoxicity in Solid Childhood Tumors.
Gündüz A; Duman D; Başbinar Y; Taşdelen B; Küpeli S; Karpuz D
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e65-e70. PubMed ID: 37828659
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk.
Linschoten M; Teske AJ; Cramer MJ; van der Wall E; Asselbergs FW
Circ Genom Precis Med; 2018 Jan; 11(1):e001753. PubMed ID: 29557343
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
15. Reducing anthracycline-induced cardiotoxicity through pharmacogenetics.
Scott E; Hasbullah JS; Ross CJ; Carleton BC
Pharmacogenomics; 2018 Oct; 19(15):1147-1150. PubMed ID: 30213233
[No Abstract] [Full Text] [Related]
16. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005008. PubMed ID: 17054232
[TBL] [Abstract][Full Text] [Related]
17. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2009 Oct; (4):CD005008. PubMed ID: 19821337
[TBL] [Abstract][Full Text] [Related]
18. Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity.
Ding Y; Du K; Niu YJ; Wang Y; Xu X
Oxid Med Cell Longev; 2022; 2022():5818612. PubMed ID: 35965684
[TBL] [Abstract][Full Text] [Related]
19. Anthracycline cardiotoxicity.
Jones RL; Swanton C; Ewer MS
Expert Opin Drug Saf; 2006 Nov; 5(6):791-809. PubMed ID: 17044806
[TBL] [Abstract][Full Text] [Related]
20. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
Aminkeng F; Bhavsar AP; Visscher H; Rassekh SR; Li Y; Lee JW; Brunham LR; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Amstutz U; Rieder MJ; Bernstein D; Carleton BC; Hayden MR; Ross CJ;
Nat Genet; 2015 Sep; 47(9):1079-84. PubMed ID: 26237429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
